Y-90 Ibritumomab (Zevalin) Radioimmunotherapy

Q: What is Y-90 ibritumomab tiuxetan (Zevalin)?

Zevalin is a radioimmunotherapy in which the anti-CD20 murine monoclonal antibody ibritumomab is joined by the chelator tiuxetan to the radionuclide yttrium-90. The antibody targets CD20 on B lymphocytes, and Y-90 delivers a high-energy beta dose to targeted and neighboring cells. It is used to treat certain B-cell non-Hodgkin lymphomas.

Q: Why does Y-90 need no gamma camera for the therapy dose?

Y-90 is essentially a pure beta emitter with no primary gamma ray, so the therapeutic dose cannot be imaged conventionally. Historically an In-111-labeled imaging dose was used to confirm biodistribution before therapy. The Y-90 distribution itself can be imaged only through bremsstrahlung SPECT or the very small internal pair-production positron branch used for Y-90 PET.

Q: How is the Zevalin dose calculated?

The therapeutic activity is weight-based and platelet-adjusted. Patients with a platelet count of 150,000/mm³ or greater receive 0.4 mCi/kg (14.8 MBq/kg); patients with mild thrombocytopenia (100,000 to 149,000/mm³) receive a reduced 0.3 mCi/kg (11.1 MBq/kg). The total administered activity must not exceed 32 mCi (1184 MBq), and patients with platelets below 100,000/mm³ are not treated.

Q: What organ receives the highest radiation absorbed dose?

In the combined dosimetry analysis of four clinical trials, the spleen received the highest median Y-90 absorbed dose at about 7.4 Gy, followed by the liver at about 4.5 Gy and the lungs at about 2.1 Gy. The kidneys and red marrow received much lower doses, and hematologic toxicity did not correlate with estimated red-marrow dose.

Q: Is Y-90 radioimmunotherapy an inpatient or outpatient treatment?

It is typically outpatient. Because Y-90 is a beta emitter with only a weak bremsstrahlung photon field, the external dose rate from the patient is low, and patients generally satisfy NRC patient-release criteria under 10 CFR 35.75 with written radiation-safety instructions rather than requiring hospitalization.

Q: How is Y-90 shielded, and why not with lead?

Beta particles are stopped by a few millimeters of low-atomic-number material such as acrylic or plastic. High-atomic-number lead is avoided as the primary shield because stopping energetic betas in high-Z material produces more bremsstrahlung x-rays. The correct approach is low-Z beta shielding first, backed by modest high-Z shielding only if needed for the bremsstrahlung component.

Y-90 ibritumomab tiuxetan (Zevalin) is a radioimmunotherapy whose physics is defined by a single fact: yttrium-90 is a high-energy, pure beta emitter with no primary gamma ray. That one property drives everything downstream — how the dose is imaged, how it is prescribed, how organs are spared, how the patient is released, and how the source is shielded.

Introduction

Radioimmunotherapy (RIT) couples the targeting specificity of a monoclonal antibody to the cell-killing power of a radionuclide. Y-90 ibritumomab tiuxetan was the first RIT agent approved in the United States for B-cell non-Hodgkin lymphoma (NHL), and it remains a clean teaching case for the physics of antibody-delivered beta therapy.¹² The antibody, ibritumomab, binds CD20 on the surface of normal and malignant B lymphocytes; the chelator tiuxetan holds either indium-111 for imaging or yttrium-90 for therapy.²³

Because Y-90 emits energetic beta particles and virtually no gamma, the agent behaves very differently from I-131 or Lu-177 therapies that carry an imageable, penetrating photon. There is no conventional post-therapy scan of the treatment dose, the external radiation field around the patient is weak, and shielding is a low-atomic-number problem rather than a lead problem. At the same time, the beta range in tissue is long enough to produce a useful "crossfire" effect that irradiates antigen-negative tumor cells near targeted ones.³⁴

This article covers the radionuclide physics of Y-90, the imaging-then-therapy (In-111/Y-90) workflow, the weight-based and platelet-driven dosing scheme with its 32 mCi cap, the organ dosimetry from the pivotal trials, and the radiation-safety and regulatory framework that makes Zevalin an outpatient therapy. DRPS supports RIT programs through PET/CT and nuclear medicine physics, radiation shielding design, and radioactive material license support across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

The radionuclide: why Y-90 is different

Yttrium-90 decays to stable zirconium-90 by beta-minus emission with a physical half-life of about 64 hours (2.67 days). The beta spectrum has a maximum energy of 2.28 MeV and a mean energy near 0.93 MeV — high enough that the particles travel a meaningful distance through tissue before stopping.⁵ The practical consequences:

Maximum beta range in soft tissue is about 11 mm, with a mean range near 2.5 mm; roughly 90% of the emitted energy is deposited within about 5 mm of the source. This crossfire range lets a targeted cell contribute dose to neighbors that may not express CD20.³⁴
There is no primary gamma emission. The therapeutic distribution cannot be imaged with a standard gamma camera. It can be visualized only through bremsstrahlung — the continuous x-rays produced when the betas decelerate in tissue — using bremsstrahlung SPECT, or through the extremely small internal pair-production branch that produces positrons and enables Y-90 PET.³
The external hazard is low. With no penetrating primary photon, the dose rate at 1 meter from a treated patient is small, which is what makes outpatient release straightforward.

Because the therapy isotope is effectively "invisible" to routine imaging, the historical Zevalin regimen used an In-111-labeled imaging dose to confirm expected biodistribution before giving the Y-90 therapy dose.²⁶

Property	In-111 ibritumomab (imaging)	Y-90 ibritumomab (therapy)
Role	Confirm biodistribution before therapy	Deliver therapeutic beta dose
Half-life	≈ 67 h (2.8 days)	≈ 64 h (2.67 days)
Principal emissions	171 and 245 keV gamma photons	Beta, E-max 2.28 MeV, mean ≈ 0.93 MeV; no primary gamma
Imaging method	Standard gamma-camera / SPECT	Bremsstrahlung SPECT or Y-90 PET only
Typical administered activity	185 MBq (5 mCi) tracer	0.3–0.4 mCi/kg, capped at 32 mCi
Primary shielding	High-Z (lead) for gammas	Low-Z (acrylic) for betas first

The In-111 imaging step confirms that the antibody distributes as expected; in current practice the imaging-dose requirement has been relaxed, but the two-radionuclide logic remains the clearest way to understand the agent.²⁶

The targeting biology in one paragraph

Ibritumomab is the parent murine antibody from which the chimeric antibody rituximab was engineered; both bind CD20.⁶ In the Zevalin regimen, an infusion of unlabeled rituximab (250 mg/m²) precedes each ibritumomab tiuxetan administration to clear circulating B cells and improve the radiolabeled antibody's biodistribution to tumor.¹² The Y-90 then delivers a continuous, exponentially decaying beta dose to CD20-expressing tissue and its immediate surroundings.

Key Technical Principles

Weight-based, platelet-adjusted dosing — and the cap

Zevalin dosing is not activity-per-lesion or MIRD-prescribed to a target dose; it is a fixed, weight-based schedule modulated by marrow reserve as reflected in the platelet count:¹²⁶

Platelets ≥ 150,000/mm³ → 0.4 mCi/kg (14.8 MBq/kg)
Platelets 100,000–149,000/mm³ (mild thrombocytopenia) → 0.3 mCi/kg (11.1 MBq/kg)
Platelets < 100,000/mm³ → do not treat
Total administered activity must not exceed 32 mCi (1184 MBq), regardless of body weight.

The cap is a hard ceiling that changes the arithmetic for heavier patients. Consider a patient with adequate platelets:

A = 0.4 \frac{mCi}{kg} \times 80 kg = 32 mCi (1184 MBq)

At exactly 80 kg the weight-based calculation reaches the cap. For a 95 kg patient the uncapped value would be:

A_{u n c a pp e d} = 0.4 \frac{mCi}{kg} \times 95 kg = 38 mCi

but the administered activity is limited to 32 mCi (1184 MBq) — the extra 6 mCi is not given. Any patient at or above roughly 80 kg on the full-dose schedule therefore receives the capped activity, a detail the authorized user and physicist must confirm when verifying the written directive and the determination of dosage under 35.63.

Organ dosimetry from the trials

A combined analysis of 179 patients from four clinical trials estimated Y-90 residence times from the In-111 biodistribution and computed organ absorbed doses. The median values were:⁷

Spleen: ≈ 7.4 Gy (highest organ dose)
Liver: ≈ 4.5 Gy
Lungs: ≈ 2.1 Gy
Kidneys: ≈ 0.23 Gy
Red marrow: ≈ 0.6 Gy (blood-based method) to ≈ 1.0 Gy (image-based method)
Total body: ≈ 0.57 Gy
Median effective blood half-life: ≈ 27 hours

A clinically important finding was that hematologic toxicity — the dose-limiting effect — did not correlate with estimated red-marrow dose, total-body dose, or blood clearance. That is why Zevalin uses a fixed weight-and-platelet schedule rather than individualized marrow dosimetry: within the eligibility criteria (< 25% marrow involvement, adequate reserve), the fixed schedule was shown to be safe.⁷

The decay math the RSO needs

Because Y-90 is unsealed byproduct material with a 64-hour half-life, waste handling is governed by simple exponential decay. The activity remaining after time t is:

A (t) = A_{0} (\frac{1}{2})^{t / T_{1/2}}

For a leftover vial or contaminated waste starting at some activity, after 5 days (120 hours):

\frac{A ( 120 )}{A _{0}} = (\frac{1}{2})^{120/64} = (\frac{1}{2})^{1.875} \approx 0.27

so about 27% remains. After roughly ten half-lives (about 27 days) the activity has fallen below 0.1% of the original, which is why Y-90 waste is well suited to decay-in-storage before disposal as ordinary waste, once surveys confirm it is indistinguishable from background.

Clinical Impact

Y-90 RIT produces high response rates in relapsed or refractory CD20-positive B-cell NHL. In the pivotal randomized comparison, the overall response rate for Zevalin was substantially higher than for rituximab alone in rituximab-naïve relapsed patients, and durable long-term responses (time to progression of 12 months or more) were documented in a meaningful fraction of treated patients on extended follow-up.⁶⁸ A phase I study extended the safety experience to children and adolescents with relapsed/refractory disease, using dosimetry-guided organ-dose limits before administering the Y-90.⁹

For the imaging and therapy service, the physics translates into concrete workflow:

A single, one-time outpatient administration rather than fractionated external-beam-style scheduling.
No routine post-therapy gamma scan of the treatment dose, though bremsstrahlung SPECT/CT or Y-90 PET can confirm distribution when clinically warranted, using the same principles applied in Y-90 bremsstrahlung imaging after radioembolization.
Predictable, low external dose to staff and family, which shapes the radiation-safety plan far more than any wall-shielding calculation.

Practical Optimization Tips

Shield beta with low-Z first. Use acrylic or high-density plastic syringe and vial shields; add a thin outer high-Z layer only to attenuate the bremsstrahlung produced in the plastic. Never make lead the first material a Y-90 beta encounters.
Verify the cap on every heavier patient. Recompute the weight-based activity and confirm the 32 mCi (1184 MBq) ceiling is applied for patients at or above about 80 kg.
Confirm platelet-based eligibility. Document platelet count and the dose tier (0.4 vs 0.3 mCi/kg) in the written directive; do not treat below 100,000/mm³.
Assay against a Y-90 setting. Use a dose calibrator setting validated for Y-90 and account for bremsstrahlung in the measurement; cross-check with the manufacturer's calibration guidance and your dose-calibrator QC program.
Plan contamination control, not structural shielding. The dominant residual hazard is beta contamination from spills and body fluids; emphasize gloves, absorbent coverings, dedicated surveys, and spill response over thick barriers.
Use decay-in-storage for waste. With a 64-hour half-life, hold waste roughly ten half-lives, survey to background, then dispose per your license.

Regulatory Considerations

Y-90 ibritumomab tiuxetan is byproduct material administered under 10 CFR Part 35, Subpart D (unsealed byproduct material requiring a written directive). The authorized user must satisfy the training and experience requirements for parenteral unsealed byproduct therapy, and each administration requires a signed written directive and adherence to the dosage-determination and record rules.¹⁰¹¹

Key regulatory anchors:

10 CFR 35.300 / 35.390 — governs the medical use of unsealed byproduct material requiring a written directive and the associated training, safety instruction, and safety precautions.¹¹
10 CFR 35.75 and NRC Regulatory Guide 8.39 — patient release criteria. Because Y-90's external photon field is weak, treated patients generally meet the dose-based release limits (5 mSv to any other individual) and are released with written radiation-safety instructions rather than admitted. The physicist should still document the release calculation and the instructions given.¹²¹³
10 CFR Part 20 — occupational and public dose limits, ALARA, contamination controls, and waste. See our overview of patient release after radiopharmaceutical therapy.
Agreement State jurisdiction. Of the states DRPS serves, Florida, Maryland, Virginia, California, and Nevada license medical use under their own Agreement-State programs, while Washington, DC is regulated directly by the NRC. Confirm which authority issues your license and any state-specific release or reporting nuances before finalizing the program.

A medical event under 10 CFR 35.3045 can arise from a dosing or administration error, so the platelet tier, weight calculation, cap, and written directive should all be independently verified before administration.

Frequently Asked Questions (FAQs)

What is Y-90 ibritumomab tiuxetan (Zevalin)?

Zevalin is a radioimmunotherapy in which the anti-CD20 murine monoclonal antibody ibritumomab is joined by the chelator tiuxetan to the radionuclide yttrium-90. The antibody targets CD20 on B lymphocytes, and Y-90 delivers a high-energy beta dose to targeted and neighboring cells. It is used to treat certain B-cell non-Hodgkin lymphomas.

Why does Y-90 need no gamma camera for the therapy dose?

Y-90 is essentially a pure beta emitter with no primary gamma ray, so the therapeutic dose cannot be imaged conventionally. Historically an In-111-labeled imaging dose was used to confirm biodistribution before therapy. The Y-90 distribution itself can be imaged only through bremsstrahlung SPECT or the very small internal pair-production positron branch used for Y-90 PET.

How is the Zevalin dose calculated?

The therapeutic activity is weight-based and platelet-adjusted. Patients with a platelet count of 150,000/mm³ or greater receive 0.4 mCi/kg (14.8 MBq/kg); patients with mild thrombocytopenia (100,000 to 149,000/mm³) receive a reduced 0.3 mCi/kg (11.1 MBq/kg). The total administered activity must not exceed 32 mCi (1184 MBq), and patients with platelets below 100,000/mm³ are not treated.

What organ receives the highest radiation absorbed dose?

In the combined dosimetry analysis of four clinical trials, the spleen received the highest median Y-90 absorbed dose at about 7.4 Gy, followed by the liver at about 4.5 Gy and the lungs at about 2.1 Gy. The kidneys and red marrow received much lower doses, and hematologic toxicity did not correlate with estimated red-marrow dose.

Is Y-90 radioimmunotherapy an inpatient or outpatient treatment?

It is typically outpatient. Because Y-90 is a beta emitter with only a weak bremsstrahlung photon field, the external dose rate from the patient is low, and patients generally satisfy NRC patient-release criteria under 10 CFR 35.75 with written radiation-safety instructions rather than requiring hospitalization.

How is Y-90 shielded, and why not with lead?

Beta particles are stopped by a few millimeters of low-atomic-number material such as acrylic or plastic. High-atomic-number lead is avoided as the primary shield because stopping energetic betas in high-Z material produces more bremsstrahlung x-rays. The correct approach is low-Z beta shielding first, backed by modest high-Z shielding only if needed for the bremsstrahlung component.

Key Takeaways

The physics starts with the emission. Y-90 is a high-energy pure beta emitter (E-max 2.28 MeV, ~64 h half-life) with no primary gamma, which sets imaging, shielding, and release strategy.
Imaging and therapy are decoupled. In-111 historically confirmed biodistribution; the Y-90 dose is visualized only by bremsstrahlung SPECT or Y-90 PET.
Dosing is fixed, weight-based, and capped. 0.4 or 0.3 mCi/kg by platelet tier, never above 32 mCi (1184 MBq), never below 100,000/mm³ platelets.
The spleen takes the highest organ dose (~7.4 Gy). Marrow toxicity did not correlate with red-marrow dose, which justifies the fixed schedule.
Shield low-Z first. Acrylic stops the betas; lead first would only make bremsstrahlung. Contamination control matters more than walls.
It is an outpatient therapy. The weak external field lets patients meet 10 CFR 35.75 release limits with written instructions.

Conclusion

Y-90 ibritumomab tiuxetan is a compact lesson in how a single nuclear property propagates through an entire clinical program. The pure-beta, no-gamma character of yttrium-90 makes the therapy dose invisible to routine imaging, keeps the external field weak enough for outpatient release, turns shielding into a low-Z problem, and makes contamination control the RSO's central concern. The fixed weight-and-platelet dosing with its 32 mCi cap, validated against combined-trial dosimetry, replaces individualized marrow calculations with a schedule shown to be safe in eligible patients.

For the physicist and RSO, a defensible Y-90 RIT program is built on the emissions: verify the activity and the cap, assay correctly for a bremsstrahlung emitter, shield with acrylic, document the release calculation, and plan waste around a 64-hour half-life. Get the physics right and the safety program follows.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and radiopharmaceutical therapy programs implement Y-90 and other RIT and theranostic agents safely and compliantly. Our support includes PET/CT and nuclear medicine physics, dose-calibrator Y-90 assay validation, beta and bremsstrahlung shielding review through radiation shielding design, patient-release calculations, waste and contamination programs, and radioactive material license support and RSO consulting.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

The aim is a therapy program where the physics, the dosing, and the safety plan all line up.

Related Resources

References

U.S. Food and Drug Administration. Zevalin (ibritumomab tiuxetan) Prescribing Information. 2009. accessdata.fda.gov
Spies SM. Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004;34(1 Suppl 1):10-13. doi:10.1053/j.semnuclmed.2003.11.004. PubMed
Society of Nuclear Medicine and Molecular Imaging. Radiopharmaceutical Therapy Central: Y-90 ibritumomab tiuxetan. snmmi.org
International Commission on Radiological Protection. ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals. Annals of the ICRP. 2019;48(1). icrp.org
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
Alcindor T, Witzig TE. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol. 2002;3(4):275-282. doi:10.1007/s11864-002-0027-y. PubMed
Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44(3):465-474. PubMed
Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109(9):1804-1810. doi:10.1002/cncr.22617. PubMed
Cooney-Qualter E, Krailo M, Angiolillo A, et al. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. Clin Cancer Res. 2007;13(18 Pt 2):5652s-5660s. doi:10.1158/1078-0432.CCR-07-1060. PubMed
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material (Subpart D, 35.300–35.396). ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR 35.75: Release of individuals containing unsealed byproduct material or implants containing byproduct material. ecfr.gov
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39: Release of Patients Administered Radioactive Material. nrc.gov